. Pse showed no effect on osteoclast apoptosis. (A) After mature osteoclasts induced by RANKL, different concentrations of Pse (0, 5, 10 μM) were used to treat the cells for additional 2 days. As a positive control for apoptosis, DNase I treatment (3,000 U/mL, 30 min) was included. Apoptotic osteoclasts were then assessed by TUNEL assay (green). Nuclei were visualized by DAPI staining. The TUNEL-positive apoptotic nuclei are indicated by white arrows. (B) The quantification of the percentage of TUNEL-positive nuclei in each group (n=5 per group). All bar graphs are presented as mean ± SD. **p<0.01 compared with the group without Pse and DNase I treatment. Scale bar=100 μm. DAPI, 4,6-diamidino-2-phenylindole; Pse, Pseurotin A; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; OC, osteoclast HMOX1 (D) , CAT (E), and GCLC (F) were examined by qPCR after 2-day RANKL stimulation in the absence or presence of Pse (5, 10 μM). Gene expression was calibrated using the Hprt1 housekeeping gene. **p<0.01 compared with the group with only RANKL treatment. CAT, catalase; GCLC, gammaglutamylcysteine synthetase; HMOX1, heme oxygenase 1; Hprt1, hypoxanthine phosphoribosyltransferase 1; Keap1, kelch like ech associated protein 1; Nox1, nicotinamide adenine dinucleotide phosphate oxidase 1; Nrf2, nuclear factor-erythroid 2 related factor 2; Pse, Pseurotin A; RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand All bar graphs are presented as mean ± SD. *p<0.05 **p<0.01 compared with control. Actb, actin beta; Alpl, alkaline phosphatase; Bglap, bone gammacarboxyglutamate protein (osteocalcin); BMP2, bone morphogenetic protein 2; Sp7/Osx, sp7 transcription factor; Tnfrsf11b, tumor necrosis factor receptor superfamily member 11b
